US President Donald Trump has announced new agreements aimed at making weight loss drugs more affordable, bringing down costs that have become a major focus of his administration’s healthcare agenda.
Speaking alongside pharmaceutical executives at the White House, President Trump unveiled deals with Eli Lilly and Novo Nordisk that will lower the monthly prices of popular obesity drugs such as Wegovy and Zepbound to between $245 and $350 for consumers. Similar GLP-1 drugs currently cost more than $1,000 a month without insurance or discounts.
Under the agreements, both companies will receive expanded access to Medicare and Medicaid, the federal healthcare programs serving seniors and low-income Americans. Eli Lilly also confirmed that it will be exempted from tariffs for three years as part of the deal.
According to senior officials, about 10% of Medicare beneficiaries will qualify for the new plan and pay only $50 for GLP-1 prescriptions. Medicaid recipients will gain access gradually, depending on when each state opts into the program. President Trump has long advocated for “most-favoured nations” pricing, a policy intended to align U.S. drug prices with those in countries with lower prices.
Also Read:
UPS Delivery Jet Crashed in Kentucky, Killing at Least Seven People
Mark Carney of Canada Pledges a “Bold” First Government Budget
